Clinical Characteristics of Japanese Type 2 Diabetic Patients Responsive to Sitagliptin

Clinical Characteristics of Japanese Type 2 Diabetic Patients Responsive to Sitagliptin - Patients Responsive to Sitagliptin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012110

Enrollment

300

Registered

2013-10-23

Start date

2013-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

50mg sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: over than HbA1c6.5%

Exclusion criteria

Exclusion criteria: liver and renal dysfunction, insulin therapy

Design outcomes

Primary

Measure	Time frame
HbA1c, HOMA-beta, HOMA-R, proinsulin/insulin, 1-5AG, adiponectin, fasting plasma glucose	—

Countries

Japan

Contacts

Public ContactKouichi Inukai

Kyorin University of Medicine Third Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism,

kinukai@ks.kyorin-u.ac.jp042-247-5512

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026